The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
3's, 48's,2's? --What are they please.
Probably me being thick but am unaware of this nomenclature.
Gje306 --Thanks for response and I take your point on the 170% increase over the year, but by low levels I mean low value compared to what most on here know it is currently worth ( and what the market should know it is worth). That is, its not reflecting value -as beinthelead points out.
On your other point --yes an update 2 weeks ago (about AGM details) but should we not be getting these at a greater rate given all the fingers in all the pies etc.
--- of the Avacta SP remaining at these low levels is not a good look, either for the company or the investors ( existing and potential). No news equates to no significant movement of the SP.
Time to increase the positive newsflow from any of the numerous pies that Avacta have their fingers in I think.
That with all of Avacta's involvements via Partnerships/Licence agreements/ Joint Ventures/Clinical Trials/Acquisitions/Etc with ( among others)
LG Chem South Korea
Daewoong Pharmaceutical South Korea
Point Biopharma Inc Indiana
Tufts University Boston
Bach Biosciences Boston
Memorial Sloan Kettering New York
Fred Hutchinson Cancer Centre Seattle
AffyXell Therapeutics South Korea
Abcam Cambridge UK
Sparta ( Single Particle Automated Raman Trapping Analysis) Imperial College, London
Royal Marsden London
The Christie Hospital Manchester
The Beatson Hospital Scotland
Coris Bioconcept Belgium
Launch Diagnostics UK
that there would be sufficient newsflow/updates to release to shareholders ( given the new spirit of improved comms etc) almost on a daily basis.
I could be wrong of course.
Stomachs not stomach's in this context --talking of scandi english.
While HMG is dithering over rejoining the Horizon European Science funding programme, a perfect opportunity arises for AS to grab the moment (and the publicity) by sending his view to the Times on the need to rejoin Horizon. It may even do the SP some good.
Until we reach the Elysian fields where news flows are strong, positive media coverage is abundant and share prices are able to move in directions other than horizontal or downwards, we remain patient and await Shaun and Consilium to work their magic on the company.
Regarding letting the general public in on the action ( which would be great if possible) its usually a three stage process in which:
1 You tell them you're going to tell them
2 You tell them
3 You tell them you've told them
Then rinse and repeat if required
Thanks travel_light ---that makes sense to me.
A couple of points on which I would appreciate assistance.
Why are the dose cohorts expressed in terms of weight (of AVA6000) per area ie in the case of the soon to be started 6th cohort its expressed as 310mg per metre squared. I would have thought it would be expressed as a weight per volume. Am sure its just me being a bit thick but I just don't get it.
Also, how near in the 6th dose cohort of AVA6000 ie at 310mg are we getting to a fatal dose of pure Dox equivalent. Thanks for your help.
Agreed BuenaVista and congratulations to AS and the team for the great science.
Would be great now to increase efforts, via Eliot Forster and Shaun Chilton perhaps, to improve the SP from its amazingly low current levels, while we all await what is probably the inevitable longer term significant rerate.
Thornogson ----and your conclusion is?
These updates are looking very professional and seem to be a gear change in the upwards direction.
Ipad----the article does not mention Avacta.
It's on page 10 of the main paper.
I am sure that AS is aware that without some positive RNS intervention prior to the AGM, the SP will continue to linger at these low levels and that shareholders consequently would not be in a happy frame of mind at the AGM, a situation he would wish to avoid perhaps. Do folk on here have any views as to when a positive RNS might land?
My guess for what it is worth is from Monday 26th June up to 7am on 28th June.
----- after coffee and biscuits, the Avacta board will seek shareholder approvals for resolutions that significantly improve the financial position of the board members --lost the will to live in the legal mumbo jumbo but that, to me, seems to be the thrust of it. As "No new material information will be discussed during the meeting" it seems logical that the board will want the shareholders to be in a good frame of mind to agree the resolutions which is why I think we will hear some SP raising good news before the meeting possibly from the left field.
Bella, as an appreciated Poster on this board, I wonder if your famed mystic powers allow you to see through the psychic mists to devine what is ahead for this company in the next couple of months?
Gruffell --the article by Colvile also mentions Lord James O'Shaughnessy, a former Health Minister whose review of Clinical trials has been given to HMG. He (O'Shaughnessy) was also present I recall at the formal opening of Scale Space with AS in September 2022.
Vertizea-Sun Ditto- its Modern Living-nothing works.
MB53 Good list, and perhaps the addition of Sparta Biodiscovery, where Dr Smith is Chair and CEO should be included for this outfit which is a front runner in Single Particle Automated Raman trapping analysis.